BIOMAT Database Logo BIOMAT Database Logo

Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. 2006

Caryn Lerman, and Rachel Tyndale, and Freda Patterson, and E Paul Wileyto, and Peter G Shields, and Angela Pinto, and Neal Benowitz
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA. clerman@mail.med.upenn.edu

BACKGROUND Nicotine is metabolized to cotinine, and cotinine is metabolized to 3'-hydroxycotinine (3-HC) by the liver enzyme cytochrome P450 (CYP) 2A6. More rapid metabolism of nicotine may result in lower nicotine blood levels from nicotine replacement products and poorer smoking cessation outcomes. This study evaluated the utility of the 3-HC/cotinine ratio as a predictor of the efficacy of nicotine replacement therapy as an aid for smoking cessation. METHODS By use of an open-label design, 480 treatment-seeking smokers were randomly assigned to 8 weeks of transdermal nicotine or nicotine nasal spray use, plus behavioral group counseling. Assessments included demographics, smoking history, body mass index, and plasma nicotine, cotinine, and 3-HC concentrations, as well as CYP2A6 genotypes. Smoking cessation was biochemically verified at the end of treatment and at 6-month follow-up. RESULTS The rate of nicotine metabolism, as indicated by pretreatment 3-HC/cotinine ratio derived from cigarette smoking, predicted the effectiveness of transdermal nicotine at both time points. The odds of abstinence were reduced by almost 30% with each increasing quartile of metabolite ratio (odds ratio, 0.72 [95% confidence interval, 0.57-0.90]; P=.005). Higher metabolite ratios also predicted lower nicotine concentrations (beta=-1.72, t(179)=-3.31, P<.001), as well as more severe cravings for cigarettes after 1 week of treatment (beta=0.32, t(190)=2.91, P=.004). The metabolite ratio did not predict cessation with use of nicotine nasal spray (odds ratio, 1.05 [95% confidence interval, 0.83-1.33]; P=.68). CONCLUSIONS The nicotine metabolite ratio might be useful in screening smokers to determine likely success with a standard dose of transdermal nicotine.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D003367 Cotinine The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties. Scotine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D016540 Smoking Cessation Discontinuing the habit of SMOKING. Giving Up Smoking,Quitting Smoking,Stopping Smoking,Cessation, Smoking,Smoking Cessations,Smoking, Giving Up,Smoking, Quitting,Smoking, Stopping,Smokings, Giving Up,Up Smoking, Giving

Related Publications

Caryn Lerman, and Rachel Tyndale, and Freda Patterson, and E Paul Wileyto, and Peter G Shields, and Angela Pinto, and Neal Benowitz
Efficacy of transdermal nicotine patches for nicotine replacement and smoking cessation.
July 1992, The Nurse practitioner,
Caryn Lerman, and Rachel Tyndale, and Freda Patterson, and E Paul Wileyto, and Peter G Shields, and Angela Pinto, and Neal Benowitz
Transdermal nicotine patch for smoking cessation.
January 1992, The New England journal of medicine,
Caryn Lerman, and Rachel Tyndale, and Freda Patterson, and E Paul Wileyto, and Peter G Shields, and Angela Pinto, and Neal Benowitz
Transdermal nicotine patch for smoking cessation.
January 1992, The New England journal of medicine,
Caryn Lerman, and Rachel Tyndale, and Freda Patterson, and E Paul Wileyto, and Peter G Shields, and Angela Pinto, and Neal Benowitz
Transdermal nicotine patch for smoking cessation.
January 1992, The New England journal of medicine,
Caryn Lerman, and Rachel Tyndale, and Freda Patterson, and E Paul Wileyto, and Peter G Shields, and Angela Pinto, and Neal Benowitz
Lack of efficacy of transdermal nicotine in smoking cessation.
October 1999, The New England journal of medicine,
Caryn Lerman, and Rachel Tyndale, and Freda Patterson, and E Paul Wileyto, and Peter G Shields, and Angela Pinto, and Neal Benowitz
Transdermal nicotine facilitates smoking cessation.
March 1990, Clinical pharmacology and therapeutics,
Caryn Lerman, and Rachel Tyndale, and Freda Patterson, and E Paul Wileyto, and Peter G Shields, and Angela Pinto, and Neal Benowitz
Transdermal nicotine after smoking cessation.
April 1994, The American journal of psychiatry,
Caryn Lerman, and Rachel Tyndale, and Freda Patterson, and E Paul Wileyto, and Peter G Shields, and Angela Pinto, and Neal Benowitz
Nicotine metabolite ratio predicts smoking topography: The Pennsylvania Adult Smoking Study.
September 2018, Drug and alcohol dependence,
Caryn Lerman, and Rachel Tyndale, and Freda Patterson, and E Paul Wileyto, and Peter G Shields, and Angela Pinto, and Neal Benowitz
Transdermal nicotine replacement and smoking cessation.
June 1992, American family physician,
Caryn Lerman, and Rachel Tyndale, and Freda Patterson, and E Paul Wileyto, and Peter G Shields, and Angela Pinto, and Neal Benowitz
Transdermal nicotine replacement smoking cessation therapy.
February 1998, The Annals of pharmacotherapy,
Copied contents to your clipboard!